Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MEGF0444A with carboplatin, paclitaxel and bevacizumab in advanced non-squamous NSCLC
2011-000711-85Phase 2Terminated
- Sponsor
- Roche
- Start
- Aug 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Non-small cell lung cancer (NS-NSCLC) comparing MEGF0444A arm with Placebo arm (2 arms). Primary endpoint: Progression-free survival. Started Aug 2011; status: terminated.
02
Drugs
parsatuzumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2011-000711-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000711-85.